Results 151 to 160 of about 2,360,518 (263)

Common gene mutations in 103 authenticated colorectal cancer cell lines. [PDF]

Oncogenesis
Kranjec C, Eilertsen IA, Nunes L, Moosavi SH, Berg KCG, Eknæs M, Hektoen M, Niederdorfer B, Lind GE, Skotheim RI, Sveen A, Lothe RA.   +11 more
europepmc   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Molecularly Imprinted Polymer Nanoparticles for Lung-Cancer-Cell-Surface Proteomics. [PDF]

Polymers (Basel)
Magumba K, Piletska E, Cao TH, Jones D, Macip S, Piletsky S.   +5 more
europepmc   +1 more source

Renal-Cell Cancer

CA: A Cancer Journal for Clinicians, 1966
openaire   +2 more sources

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

HSP90α and KLK6 Coregulate Stress-Induced Prostate Cancer Cell Motility. [PDF]

Cells
O'Neill KL, Zigmond JW, Bergan R.
europepmc   +1 more source

Small cell lung cancer

Lung Cancer, 1997
D, Ihde, B, Souhami, R, Comis, A, Gregor, H, Hansen, B, Johnson, N, Murray, P, Postmus, P, Rocmans, N, Saijo, R, Stout, A, Turrisi, H, Wagner   +12 more
openaire   +4 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

DHX15 overexpression suppresses colorectal cancer cell line proliferation. [PDF]

Oncol Lett
Ii Y, Saita K, Iwagawa T, Ito S, Sugimoto K, Sakamoto K, Watanabe S.   +6 more
europepmc   +1 more source

THE DORMANT CANCER CELL [PDF]

Obstetrical & Gynecological Survey, 1954
openaire   +2 more sources